Beta-receptor blocking drugs are used in the treatment all of the following diseases EXCEPT:

Questions 52

ATI RN

ATI RN Test Bank

Cardiovascular Drug Questions

Question 1 of 5

Beta-receptor blocking drugs are used in the treatment all of the following diseases EXCEPT:

Correct Answer: C

Rationale: The correct answer is C: Pheochromocytoma. Beta-receptor blocking drugs are contraindicated in pheochromocytoma because they can potentially worsen hypertension due to unopposed alpha-adrenergic effects. Choice A is correct as beta-blockers are commonly used in hypertension, ischemic heart disease, and cardiac arrhythmias. Choice B is incorrect as beta-blockers are used in the treatment of glaucoma to reduce intraocular pressure. Choice D is incorrect as beta-blockers are used to manage symptoms of hyperthyroidism such as tachycardia and tremors.

Question 2 of 5

Indicate the drug that induces parkinsonian syndromes:

Correct Answer: A

Rationale: Certainly! Chlorpromazine is the correct answer as it is a typical antipsychotic known to induce parkinsonian syndromes as a side effect due to its dopamine-blocking properties. This leads to a decrease in dopamine levels and imbalance in the basal ganglia function, resulting in symptoms resembling Parkinson's disease. Diazepam, Triazolam, and Carbamazepine do not typically induce parkinsonian syndromes as they do not directly affect dopamine levels or basal ganglia function.

Question 3 of 5

Which of the following opioid analgesics can produce an increase in the pulmonary arterial pressure and myocardial work?

Correct Answer: B

Rationale: The correct answer is B: Pentazocine. Pentazocine is a mixed opioid agonist-antagonist that can increase pulmonary arterial pressure and myocardial work due to its kappa agonist activity. Morphine (A) primarily acts on mu-opioid receptors and does not significantly affect pulmonary arterial pressure. Meperidine (C) can cause hypotension rather than an increase in pulmonary arterial pressure. Methadone (D) is a synthetic opioid that has a long duration of action but does not typically cause a significant increase in pulmonary arterial pressure or myocardial work.

Question 4 of 5

Indicate the nonopioid agent of central effect with analgesic activity:

Correct Answer: C

Rationale: The correct answer is C: Clopheline. Clopheline is a centrally acting alpha-2 adrenergic agonist known for its analgesic effects by modulating pain perception in the central nervous system. Reserpine (A) is not an analgesic drug but rather a monoamine depletor. Propranolol (B) is a beta-blocker primarily used for cardiac conditions, not for its analgesic properties. Prazosin (D) is an alpha-1 adrenergic antagonist mainly used for hypertension and not known for its analgesic effects. Therefore, the correct answer is C as it directly acts on the central nervous system to provide analgesia.

Question 5 of 5

Which of the following antidepressants is a selective short-acting MAO-A inhibitor?

Correct Answer: C

Rationale: The correct answer is C: Moclobemide. Moclobemide is a selective short-acting MAO-A inhibitor, which means it specifically targets the MAO-A enzyme, leading to increased levels of serotonin and norepinephrine. This helps alleviate symptoms of depression. Maprotiline (A) is a tetracyclic antidepressant, Amitriptyline (B) is a tricyclic antidepressant, and Selegiline (D) is a MAO-B inhibitor used for Parkinson's disease, not for depression. Therefore, C is the correct answer as it matches the criteria of being a selective short-acting MAO-A inhibitor.

Access More Questions!

ATI RN Basic


$89/ 30 days

ATI RN Premium


$150/ 90 days

Similar Questions